...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Development of microspheres for neurological disorders: From basics to clinical applications
【24h】

Development of microspheres for neurological disorders: From basics to clinical applications

机译:用于神经系统疾病的微球的开发:从基础到临床应用

获取原文
获取原文并翻译 | 示例

摘要

Drug delivery to the central nervous system remains a challenging area of investigation for both basic and clinical neuroscientists. Numerous drugs are generally excluded from blood to blain transfer due to the negligible permeability of the brain capillary endothelial wall, which makes up the blood brain barrier in vivo. For several years, we have explored the potential applications of the microencapsulation of therapeutic agents to provide local controlled drug release in the central nervous system. Due to their size, these microparticles can be easily implanted by stereotaxy in discreet, precise and functional areas of the brain without damaging the surrounding tissue. This type of implantation avoids the inconvenient insertion of large implants by open surgery and can be repeated if necessary. We have established the compatibility of poly(lactide-co-glycolide) microspheres with brain tissues. Presently, the most developed applications concern Neurology and Neuro-oncology, with local delivery of neurotrophic factors and antimitotic drugs into neurodegenerative lesions and brain tumours, respectively. The drugs that had been encapsulated by our group included nerve growth factor (NGF), 5-fluorouracil (5-FU), idoxuridine and BCNU. Preclinical studies have been performed with each drug. Studies with NGF are reported as an example. A phase I/II clinical trial has been carried out in patients with newly diagnosed glioblastomas to assess the potentialities of 5-FU-loaded microspheres when intracranially implanted. (C) 2000 Elsevier Science B.V. All rights reserved. [References: 95]
机译:对于基础和临床神经科学家来说,将药物输送到中枢神经系统仍然是一个充满挑战的研究领域。由于脑毛细血管内皮壁的渗透性可忽略不计,因此通常将许多药物从血液转移至白蛋白转移,这在体内构成了血脑屏障。几年来,我们已经探索了微囊化治疗剂在中枢神经系统中提供局部控制药物释放的潜在应用。由于它们的大小,这些微粒可以通过立体定位很容易地植入大脑的谨慎,精确和功能区域,而不会损坏周围的组织。这种植入避免了通过开放手术不方便地插入大型植入物,并且在必要时可以重复进行。我们已经建立了聚(丙交酯-共-乙交酯)微球与脑组织的相容性。目前,最发达的应用涉及神经病学和神经肿瘤学,它们分别将神经营养因子和抗有丝分裂药物局部递送到神经退行性病变和脑肿瘤中。我们小组封装的药物包括神经生长因子(NGF),5-氟尿嘧啶(5-FU),异氧尿苷和BCNU。每种药物均已进行了临床前研究。以NGF研究为例。 I / II期临床试验已在患有新诊断的胶质母细胞瘤的患者中进行,以评估颅内植入时负载5FU的微球的潜力。 (C)2000 Elsevier Science B.V.保留所有权利。 [参考:95]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号